Apr 7, 2015
CALGARY, April 7, 2015 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) announces that it has received two China patent approvals covering RVX-208. A composition of matter patent, China No. 2007 8 0052349.8 titled, "Compounds for the Prevention and Treatment of Cardiovascular Disease" was granted until February 2027. A manufacturing patent, China No. ZL 2009 8 0106586.7 titled, "Methods of Preparing Quinazolinone Derivatives" was granted until June 2029.
"These two additional patents build upon the growing intellectual property estate for our core asset, RVX-208. With our Chinese patent life extending out to June 2029, RVX-208 now has the necessary protection required for a regional licensing deal in China," stated Donald McCaffrey, president and CEO of Resverlogix. Mr. McCaffrey added, "Resverlogix views the ever expanding Chinese pharmaceutical market as an attractive opportunity which aligns with our regional licensing strategy. We will continue our discussions with potential partners at the China Bio Partnering Forum in Shanghai next week." On April 15th, Resverlogix is one of four selected Canadian companies who will be presenting at China Bio.
About RVX-208
RVX-208 is a first-in-class, small molecule selective BET bromodomain inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can turn disease-causing genes off, returning them to a healthier state. RVX-208 is the first and only BET inhibitor selective for BRD4-BD2, producing a nexus of biological effects with potentially important benefits for patients with diseases such as cardiovascular disease (CVD), diabetes mellitus (DM), Alzheimer's disease, peripheral artery disease, and chronic kidney disease while maintaining an excellent safety profile. Resverlogix is planning to study RVX-208 in a proposed Phase 3 clinical trial in CVD patients with DM and low HDL.
About Resverlogix
Resverlogix Corp. is developing RVX-208, a first-in-class, small molecule selective BET bromodomain inhibitor for the potential treatment of patients with cardiovascular disease, diabetes mellitus, Alzheimer's disease, peripheral artery disease, and chronic kidney disease. RVX-208 is the only selective BET bromodomain inhibitor in clinical trials. Resverlogix's common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com. We can be followed on our blog at http://www.resverlogix.com/blog and via Twitter https://twitter.com/resverlogix_rvx @Resverlogix_RVX.
This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to research and development activities and the potential role of RVX-208 in the treatment of cardiovascular disease, Alzheimer's disease, peripheral artery disease and chronic kidney disease. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For further information, please contact:
Company Contacts:
Donald J. McCaffrey
President and CEO
Resverlogix Corp.
Phone: 403-254-9252
Email: don@resverlogix.com
Sarah Zapotichny
Director, Investor Relations & Corporate Communications
Resverlogix Corp.
Phone: 403-254-9252
Email: sarah@resverlogix.com
Media:
Tony Russo, Ph.D.
Matt Middleman, M.D.
Russo Partners, LLC
Phone: 212 845 4251
Phone: 212-845-4272
Email: tony.russo@russopartnersllc.com
Email: matt.middleman@russopartnersllc.com
SOURCE Resverlogix Corp.